The Effects of Semaglutide on Body Composition and Performance in Military Personnel

What Was Tested

The trial (phase 4) is built around Semaglutide.

This epidemic extends its impact to chronic diseases and escalating healthcare expenses.

It had 1 arm (groups): Semaglutide Treatment (experimental).

The registry classes the interventions as drug.

Who Took Part

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Active-duty military personnel. Age ≥ 18 years at the time of signing informed consent. Body mass index (BMI) ≥ 30 kg/m2 or ≥ 27 kg/m2 with the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, etc.). History of at least one self-reported effort to lose body weight. Ability to exercise ≥ 3x per week during the study.

The full record lists 5 inclusion and 17 exclusion criteria; among the exclusions: currently in basic combat training, advanced individual training, or one station unit training, or equivalence in other military services; history of cholecystectomy; personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia type 2.

How the Study Was Run

Design: single-group and open-label.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2024-08-01 with completion listed for 2025-03-27.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Weight Loss (time frame: 24 weeks). Body composition (time frame: 24 weeks). Physical Performance (time frame: 24 weeks).

It also tracked 2 secondary outcomes, for example Weight Loss Maintenance and Eating habits and mediators of eating behavior.

What This Means in Plain Language

Put simply, this is a phase 4 trial of Semaglutide in people.

It was withdrawn before enrolling anyone; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.